Chronic Hepatitis B Clinical Trial
Official title:
A 48-week Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B
Verified date | October 2009 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
This 48-week open-label study of local manufactured adefovir dipivoxil Tablet evaluates the efficacy and safety of adefovir 10mg once daily in Chinese subjects with compensated CHB. Primary endpoint is proportion of subjects achieving HBV DNA undetectable (<=1000 copies/mL by by Roche COBAS AMPLICOR HBV MONITOR Test) at week 48. Approximately 1250 patients will be recruited in 30 study centers in China. The subjects are offered 48 weeks of open label adefovir dipivoxil treatment, with assessments every three months, after with is a 12-week post study treatment follow-up prior to study completion.
Status | Completed |
Enrollment | 1470 |
Est. completion date | September 2008 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male or female subjects aged 18-65 years inclusive - Documented chronic hepatitis B infection determined by the presence of serum HBsAg for a least 6 months - Serum HBV DNA =105 copies/ml for HBeAg positive subjects or =104 copies/ml for HBeAg negative subjects (Real-time PCR, LLQ=1000cp/ml) at study screening (within 2 weeks before baseline), respectively. - ALT value =2 times the upper limit of normal (ULN) at the time of screening, as determined using laboratory ranges and documented ALT abnormal within 6 month prior the study screening. - Compensated liver disease with the following laboratory and clinical parameters study screening: - prothrombin time = 2 seconds above normal direct bilirubin - Albumin=35g/L - Total bilirubin =2.5mg/dL (= 43 µmol/L) or normal direct bilirubin - No history of variceal bleeding - No history of encephalopathy - No history of ascites - Willing and able to undergo two liver biopsies (prior to dosing, and after 48 weeks of therapy; only apply to subjects who are enrolled to the sites where liver biopsy is required). - Agree not to participate in any other investigational trials or to undertake other HBV systemic antiviral regimens during participation in this study Exclusion Criteria: A subject will not be eligible for inclusion in this study if any of the following criteria apply: - Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include, may not limit to, renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, active infection or cancer. - Documented evidence of active liver disease due to other causes including - co-infection hepatitis C (HCV), Subjects who are anti-HCV positive and in whom HCV RNA is undetectable are considered to be HCV seropositive and will not be eligible - co-infection with hepatitis delta (HDV) - co-infection with HIV - autoimmune hepatitis (antinuclear antibody titre>1:160) - Alanine aminotransferase(ALT) > 10 times ULN at screening or history of acute exacerbation leading to transient decompensation - Serum alpha fetoprotein (AFP) >50 ng/mL. - Hepatocellular carcinoma as evidenced by one of the following: - suspicious foci on ultrasound or radiological examination - where no positive ultrasound finding, but serum alpha-fetoprotein > 100ng/ml - Adequate renal function defined as serum creatinine >1.5 mg/dL (>130 µmol/L) - Adequate hematological function defined as: - Absolute neutrophil count <1 x 10³/mm³ (1 x 10^9/L) - Platelets<80 x 10³/mm³ (80 x 10^9/L); platelets<100 x 10³/mm³ (100 x 10^9/L) - Hemoglobin<12g/dL (120 g/L)(males) or <10 g/dL (100 g/L) (females) - Active alcohol or drug abuse or history of alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results. - Use of immunosuppressive therapy, immunomodulatory therapy (including interferon or thymosin), systemic cytotoxic agents within the previous 6 months or during the study. - Use of chronic anti-viral agents(e.g. lamivudine, adefovir dipivoxil, entecavir, famciclovir, tenofovir, FTC, ganciclovir, DAPD, LfMA, HBIg, etc.), Chinese herbal medicines known to have activity against HBV within the previous 3 months or during the study; use of agents with effect of ALT reduction (e.g. schisandra agents) during the study. - Received nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cis-platinum, pentamidine etc.) or competitors of renal excretion (e.g., probenecid within 2 months prior to study screening or the expectation that patient will receive any of these during the course of the study. - Received hepatotoxic drugs (e.g., anabolic steroids, ketaconazole, itraconazole, isoniazid, rifampin, rifabutin) within 2 months prior to study screening or expected to receive these during the course of the study. - Previous (or planned) participation in an investigational trial involving administration of investigational compound within 2 months prior to the study screening. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | GSK Investigational Site | Beijing | |
China | GSK Investigational Site | Beijing | |
China | GSK Investigational Site | Beijing | |
China | GSK Investigational Site | Beijing | |
China | GSK Investigational Site | Changchun | Jilin |
China | GSK Investigational Site | Changsha | |
China | GSK Investigational Site | Changsha | |
China | GSK Investigational Site | Chengdu | Sichuan |
China | GSK Investigational Site | Chongqing | |
China | GSK Investigational Site | Chongquin | |
China | GSK Investigational Site | Fuzhou | |
China | GSK Investigational Site | Guangzhou | Guangdong |
China | GSK Investigational Site | Guangzhou | Guangdong |
China | GSK Investigational Site | Hangzhou | Zhejiang |
China | GSK Investigational Site | Jinan | |
China | GSK Investigational Site | Nanjing | Jiangsu |
China | GSK Investigational Site | Nanjing | Jiangsu |
China | GSK Investigational Site | Nanjing | Jiangsu |
China | GSK Investigational Site | Shanghai | |
China | GSK Investigational Site | Shanghai | |
China | GSK Investigational Site | Shanghai | |
China | GSK Investigational Site | Shanghai | |
China | GSK Investigational Site | Shanghai | |
China | GSK Investigational Site | Tianjin | |
China | GSK Investigational Site | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) <1000 Copies/Milliliter at Week 48 | Week 48 | No | |
Secondary | Number of HBeAg Positive Participants Achieving Histological Improvement at Week 48 | Week 48 | No | |
Secondary | Ranked Assessment of Liver Histology in HBeAg Positive Participants From Baseline to Week 48 | Baseline to Week 48 | No | |
Secondary | Change From Screening in Median Serum HBV DNA at Weeks 24 and 48 | Weeks 24 and 48 | No | |
Secondary | Number of Participants Achieving ALT (Alanine Aminotransferase) Normalization at Week 48 | Week 48 | No | |
Secondary | Number of HBeAg Positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Week 48 | Week 48 | No | |
Secondary | Number of Participants With ADV-associated Resistance at Week 48 | Week 48 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04496882 -
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
|
Phase 4 | |
Completed |
NCT04083716 -
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT03038802 -
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
|
Phase 1/Phase 2 | |
Completed |
NCT05310487 -
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT06070051 -
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
|
Phase 1 | |
Terminated |
NCT05001022 -
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
|
Phase 1 | |
Recruiting |
NCT04139850 -
The Establishment of Korean Hepatitis B Patients Cohort
|
||
Recruiting |
NCT05343481 -
Efficacy of VTP-300 in Chronic Hepatitis B Infection
|
Phase 2 | |
Not yet recruiting |
NCT05490836 -
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
|
N/A | |
Recruiting |
NCT04543565 -
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
|
Phase 3 | |
Active, not recruiting |
NCT02894918 -
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
|
Phase 4 | |
Not yet recruiting |
NCT02793791 -
Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients
|
N/A | |
Recruiting |
NCT02287857 -
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
|
N/A | |
Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
Recruiting |
NCT01491295 -
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
|
Phase 4 | |
Terminated |
NCT01872988 -
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
|
Phase 3 | |
Recruiting |
NCT01487876 -
Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
|
Phase 2 | |
Not yet recruiting |
NCT01436539 -
Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients
|
Phase 4 | |
Completed |
NCT01531166 -
A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon
|
N/A | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A |